Pharmacokinetics and tolerability of intravenous cefotetan disodium for injection in healthy Chinese volunteers: A randomized, open-label, single- and multiple-dose study

Clinical Therapeutics

Volumn 32, Issue 10, 2010, Pages 1832-1841

  Shi, Shaojun ^a   Liu, Yani ^a   Li, Zhongfang ^a   Zheng, Heng ^a   Lv, Yongning ^a   Chen, Hui ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Cefotetan disodium; Healthy; Pharmacokinetics; Safety; Subjects

Indexed keywords

CEFOTETAN; GENERIC DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHINESE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; INJECTION SITE PHLEBITIS; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; MULTIPLE DRUG DOSE; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SINGLE DRUG DOSE;

ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CEFOTETAN; CHINA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; YOUNG ADULT;

EID: 78650627439     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.09.015     Document Type: Article

References (27)

1. Gribble MJ Cefotetan: A secondgeneration cephalosporin active against anaerobic bacteria. CMAJ 1994, 151:537-542. Committee on Antimicrobial Agents, Canadian Infectious Disease SocietyCanadian Infectious Disease Society.
2. Chapman SJ, Owen J Randomized trial of single-dose versus multiple-dose cefotetan for the postpartum treatment of intrapartum chorioamnionitis. Am J Obstet Gynecol. 1997, 177:831-834.
3. Vinogradova MA, Kozko TD, Petukhov EM, et al. Effectiveness of cefotetan in clinical practice [in Russian]. Antibiot Khimioter. 1997, 42:16-19.
4. Goldstein EJ, Citron DM, Merriam CV, Abramson MA Infection after elective colorectal surgery: Bacteriological analysis of failures in a randomized trial of cefotetan vs. ertapenem prophylaxis. Surg Infect (Larchmt). 2009, 10:111-118.
5. Jeong WK, Park JW, Lim SB, et al. Cefotetan versus conventional triple antibiotic prophylaxis in elective colorectal cancer surgery. J Korean Med Sci. 2010, 25:429-434.
6. Itani KM, Wilson SE, Awad SS, et al. Ertapenem versus cefotetan prophylaxis in elective colorectal surgery. N Engl J Med. 2006, 355:2640-2651.
7. Itani KM, Jensen EH, Finn TS, et al. Effect of body mass index and ertapenem versus cefotetan prophylaxis on surgical site infection in elective colorectal surgery. Surg Infect (Larchmt). 2008, 9:131-137.
8. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010, 50:133-164. [published correction appears in Clin Infect Dis. 2010;50:1695].
9. Cefotan (cefotetan disodium) for injection Accessed May 14, 2010. http://www.drugs.com/pro/cefotan.html.
10. Moine P, Asehnoune K Antibiotic prophylaxis in colorectal surgery. N Engl J Med. 2007, 356:1684. Letter.
11. Bratzler DW, Houck PM Antimicrobial prophylaxis for surgery: An advisory statement from the National Surgical Infection Prevention Project. Am J Surg. 2005, 189:395-404. Surgical Infection Prevention Guideline Writers Workgroup.
12. Allen JW, Acosta J, Casós SR, et al. Cefotetan-induced hemolytic anemia after bariatric procedures. Surg Obes Relat Dis. 2006, 2:393-396.
13. Perkins J Fatal drug-induced immune hemolytic anemia due to cefotetan; A case study. Asian J Transfus Sci. 2008, 2:20-23.
14. Martin C, Thomachot L, Albanese J Clinical pharmacokinetics of cefotetan. Clin Pharmacokinet. 1994, 26:248-258.
15. Carver PL, Nightingale CH, Quintiliani R Pharmacokinetics and pharmacodynamics of total and unbound cefoxitin and cefotetan in healthy volunteers. J Antimicrob Chemother. 1989, 23:99-106.
16. Guibert J, Kitzis MD, Yvelin C, Acar JF Pharmacokinetics of single intravenous and intramuscular doses of cefotetan in normal human volunteers. J Antimicrob Chemother. 1983, 11(Suppl):201-206.
17. Yates RA, Adam HK, Donnelly RJ, et al. Pharmacokinetics and tolerance of single intravenous doses of cefotetan disodium in male Caucasian volunteers. J Antimicrob Chemother. 1983, 11(Suppl):185-191.
18. Yates RA, Cockshott ID, Houghton HL, et al. Pharmacokinetics and tolerance of single intramuscular doses of cefotetan in normal Caucasian volunteers. J Antimicrob Chemother. 1983, 11(Suppl):207-212.
19. Adam HK, Houghton HL, Yates RA, et al. Pharmacokinetics and tolerance of a 24-h infusion of cefotetan disodium (with and without loading dose) in normal Caucasian volunteers. J Antimicrob Chemother. 1983, 11(Suppl):193-199.
20. Ohkawa M, Hirano S, Tokunaga S, et al. Pharmacokinetics of cefotetan in normal subjects and patients with impaired renal function. Antimicrob Agents Chemother. 1983, 23:31-35.
21. Nakagawa K, Koyama M, Tachibana A, et al. Pharmacokinetics of cefotetan (YM09330) in humans. Antimicrob Agents Chemother. 1982, 22:935-941.
22. Good Clinical Practice guideline [in Chinese] State Food and Drug Administration, Accessed May 14, 2010. http://www.sda.gov.cn/WS01/CL0053/24473.html.
23. ICH Topic E 6 (R1): Guideline for Good Clinical Practice. Note for guidance on good clinical practice European Medicines Agency, Accessed May 14, 2010. http://www.ema.europa.eu/pdfs/human/ich/013595en.pdf.
24. World Medical Association Declaration of Helsinki-ethical principles for medical research involving human subjects Accessed May 14, 2010. http://www.wma.net/en/30publications/10policies/b3/index.html.
25. Guidance for clinical pharmacokinetic studies of chemical drugs [in Chinese] State Food and Drug Administration, Accessed May 15, 2010. http://www.sda.gov.cn/gsz05106/07.pdf.
26. Péhourcq F, Jarry C Determination of third-generation cephalosporins by high-performance liquid chromatography in connection with pharmacokinetic studies. J Chromatogr A. 1998, 812:159-178.
27. Chen ZY, Zheng QS, Sun RY Functions of the DAS software for pharmacological calculation. Chin J Clin Pharmacol Ther. 2002, 7:562-564.